Apomorphine in patients with Parkinson's disease
Identifieur interne : 000268 ( France/Analysis ); précédent : 000267; suivant : 000269Apomorphine in patients with Parkinson's disease
Auteurs : D. Muguet [France] ; E. Broussolle [France] ; G. Chazot [France]Source :
- Biomedicine & Pharmacotherapy [ 0753-3322 ] ; 1995.
English descriptors
- KwdEn :
Abstract
We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D1 and D2 dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180μg/kg. Plasma maximal concentration is reached in 8–16 minutes, with a plasma half life of 34–70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses are able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the “off” motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In somes cases, continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone, a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual, and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of a better understanding of the pathophysiology of Parkinson's disease.
Url:
DOI: 10.1016/0753-3322(96)82620-5
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 000054
- to stream Main, to step Curation: 000043
- to stream Main, to step Exploration: 002357
- to stream France, to step Extraction: 000268
Links to Exploration step
ISTEX:FAE9740E546EECA9AA99EE634617729121C6CB1ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine in patients with Parkinson's disease</title><author><name sortKey="Muguet, D" sort="Muguet, D" uniqKey="Muguet D" first="D" last="Muguet">D. Muguet</name></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name></author><author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FAE9740E546EECA9AA99EE634617729121C6CB1A</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0753-3322(96)82620-5</idno><idno type="url">https://api.istex.fr/document/FAE9740E546EECA9AA99EE634617729121C6CB1A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000054</idno><idno type="wicri:Area/Main/Curation">000043</idno><idno type="wicri:Area/Main/Exploration">002357</idno><idno type="wicri:Area/France/Extraction">000268</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Apomorphine in patients with Parkinson's disease</title><author><name sortKey="Muguet, D" sort="Muguet, D" uniqKey="Muguet D" first="D" last="Muguet">D. Muguet</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie C, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, 59 boulevard Pinel, 69003 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie C, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, 59 boulevard Pinel, 69003 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie C, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, 59 boulevard Pinel, 69003 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Biomedicine & Pharmacotherapy</title><title level="j" type="abbrev">BIOPHA</title><idno type="ISSN">0753-3322</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="197">197</biblScope><biblScope unit="page" to="209">209</biblScope></imprint><idno type="ISSN">0753-3322</idno></series><idno type="istex">FAE9740E546EECA9AA99EE634617729121C6CB1A</idno><idno type="DOI">10.1016/0753-3322(96)82620-5</idno><idno type="PII">0753-3322(96)82620-5</idno><idno type="ArticleID">96826205</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0753-3322</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>apomorphine</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We present a review of the recent literature and personal experience with apomorphine in patients with Parkinson's disease. Apomorphine is a potent D1 and D2 dopaminergic agonist. It has a rapid and short duration effect after subcutaneous administration at doses ranging from 15 to 180μg/kg. Plasma maximal concentration is reached in 8–16 minutes, with a plasma half life of 34–70 minutes. Bioavailability is close to 100%. Repeated injections in patients show post-stimulative hyposensitivity. Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness. Appropriate doses are able to alleviate akinesia, rigidity and tremor. Recent therapeutic trials have demonstrated the high interest of intermittent multiple subcutaneous apomorphine injections to cut the “off” motor phases in fluctuating parkinsonian patients under chronic levodopa treatment. In somes cases, continuous apomorphine subcutaneous infusion with a portable pump may be required, particularly when levodopa treatment is temporarily interrupted, as after abdominal sugery. During long-term treatment, the apomorphine dose able to relieve akinesia remains stable. Peripheral side effects such as nausea and hypotension may be prevented by the co-administration of domperidone, a peripheral dopaminergic antagonist. Cutaneous fibrous nodules and psychiatric symptoms may occur, but usually at high dosages with continuous infusion. Local allergic effects have limited the use of other routes of administration, such as intranasal, sublingual, and rectal routes. Apomorphine is also used as a pharmacological tool for clinical research with the aim of a better understanding of the pathophysiology of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Muguet, D" sort="Muguet, D" uniqKey="Muguet D" first="D" last="Muguet">D. Muguet</name></region><name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name><name sortKey="Chazot, G" sort="Chazot, G" uniqKey="Chazot G" first="G" last="Chazot">G. Chazot</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000268 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000268 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:FAE9740E546EECA9AA99EE634617729121C6CB1A
|texte= Apomorphine in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |